Overture Life has secured a €20 million ($21.2 million) loan from the European Investment Bank to invest in automation of assisted reproductive processes and AI to improve IVF pregnancy outcomes and fertility preservation. The financing will support R&D, manufacturing scale-up, and clinical trials as well as commercialization in Europe of products including Overture Life’s DaVitri vitrification platform and non-invasive metabolomics-based tools to enhance detection of embryos’ suitability for implantation in IVF.
The DaVitri platform is a tabletop device that automates the vitrification preparation of human mature oocytes, enabling egg freezing beyond throughput-constrained fertility clinics. The device is designed to integrate with existing and new embryology labs.
“We are delighted to join forces with research-intensive startups like Overture to expand the range of healthcare and medical solutions available to European citizens,” said Alessandro Izzo, EIB Director of Equity, Growth Capital and Project Finance. “This new financing shows the EIB’s commitment to support technological innovation and the use of AI to develop breakthrough medical solutions.”
“This new funding from our partners at EIB is more than just financial support,” said Hans Gangeskar, Overture Life’s CEO. “This is a signal that Europe understands the personal and demographic urgency of reproductive freedom. The EU has shown its willingness to make long-term public investments in fertility infrastructure and support new technologies, and we hope to see other jurisdictions follow the same path.”
The financing is backed by the InvestEU programme and contributes to the EIB’s TechEU initiative, which aims to mobilize €250 billion in investments by 2027 for startups, scale-ups and innovative companies across Europe.
Overture Life has raised approximately $70 million (€66 million) in total funding, including a recent venture capital round in the United States. The company’s investors include Overwater Ventures, GV, Khosla Ventures, and Octopus Ventures.
The DaVitri device launched earlier in 2025 in multiple countries across South and Central America, most recently in Brazil. The device is in clinical testing in the United States, where IVF cycles cost $15,000 or more.
Overture Life’s ICSI.A robot resulted in the first two live births from an automated fertilization device in 2023. The company’s m|z platform for non-invasive embryo selection is accessible through a CLIA-certified laboratory in Texas.
The company has R&D operations in Spain and active operations in the United States.
